Wellness & Lifestyle – Page 2

Understanding Legionnaires’ Disease: A Public Health Concern

By MedXY 08/02/2025

Legionnaires’ disease is a severe lung infection caused by bacteria in contaminated water systems. Recent cases in NYC highlight the importance of prevention and management.

Clinical Updates Wellness & Lifestyle

Alcon’s Tryptyr: A New Neuromodulatory Approach for Rapid Dry Eye Relief

By MedXY 08/02/2025

Alcon introduces Tryptyr, the first TRPM8 agonist eye drop, promising rapid tear production for dry eye disease. FDA-approved in May 2024 following robust phase 3 trials.

Medical News Wellness & Lifestyle

Declining Vaccination Rates Among US Kindergarteners: A Growing Public Health Concern

By MedXY 08/02/2025

Vaccination rates for US kindergarteners have declined for the third consecutive year, raising public health concerns. Experts attribute this trend to increased vaccine hesitancy and misinformation.

Clinical Updates Wellness & Lifestyle

FDA Approves Once-Daily Vizz (Aceclidine Ophthalmic Solution 1.44%) for Presbyopia: Clinical Implications and Evidence Review

By MedXY 08/02/2025

The FDA has approved Vizz, a once-daily aceclidine ophthalmic solution, for presbyopia in adults based on robust phase 3 data. The eye drop offers up to 10 hours of improved near vision with a favorable safety profile.

Clinical Updates Wellness & Lifestyle

Oveporexton: A Promising Orexin Receptor 2 Agonist for Narcolepsy Type 1 – Results from a Phase 2 Randomized Trial

By MedXY 08/02/2025

Oveporexton, an oral orexin receptor 2–selective agonist, demonstrated significant improvements in wakefulness and cataplexy in narcolepsy type 1 patients over 8 weeks, with manageable adverse events.

Clinical Updates Wellness & Lifestyle

Advances in Second-Line Antiretroviral Therapy for Children with HIV in Africa: Insights from the CHAPAS-4 Trial

By MedXY 08/02/2025

TAF–emtricitabine and dolutegravir-based regimens outperform standard options as second-line ART for African children with HIV, offering improved viral suppression and safety.

Clinical Updates Wellness & Lifestyle

Comparative Efficacy and Safety of Tolebrutinib in Multiple Sclerosis: Insights from Recent Phase 3 Trials

By MedXY 08/02/2025

Tolebrutinib reduced disability progression in nonrelapsing secondary progressive MS but did not surpass teriflunomide in reducing relapse rates in relapsing MS. Safety signals include elevated liver enzymes and minor bleeding risks.

Clinical Updates Wellness & Lifestyle

Sotatercept in High-Risk Pulmonary Arterial Hypertension: A Landmark Advance in Patient Outcomes

By MedXY 08/02/2025

Sotatercept significantly reduces the risk of death, lung transplantation, or hospitalization in high-risk pulmonary arterial hypertension patients, marking a major advance in the management of this life-threatening disease.

Clinical Updates Wellness & Lifestyle

Upadacitinib and Janus Kinase Inhibitors in Giant-Cell Arteritis: Clinical Trial and Real-World Evidence

By MedXY 08/02/2025

Upadacitinib at 15 mg with a 26-week glucocorticoid taper shows superior efficacy and comparable safety to placebo in giant-cell arteritis. Real-world data suggest JAK inhibitors, including upadacitinib, may benefit relapsing cases unresponsive to conventional therapies.

Clinical Updates Wellness & Lifestyle

Navigational Bronchoscopy Versus Transthoracic Needle Biopsy for Peripheral Lung Nodules: New Evidence from the VERITAS Trial

By MedXY 08/02/2025

Navigational bronchoscopy offers noninferior diagnostic accuracy to transthoracic needle biopsy for peripheral pulmonary nodules, with notably fewer pneumothorax complications.